BioRestorative Therapies's EBIT per Share for the
three
months ended in Mar. 2026 was €-0.17.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.18.
During the past 3 years, the average EBIT per Share Growth Rate was 30.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 29.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 64.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for BioRestorative Therapies's EBIT per Share or its related term are showing as below:
FRA:9OF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 2.3 Med: 60.4 Max: 90.3
Current: 30.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of BioRestorative Therapies was 90.30% per year. The lowest was 2.30% per year. And the median was 60.40% per year.
FRA:9OF's 3-Year EBIT Growth Rate is ranked better than 69.1% of 1178
companies
in the Biotechnology industry
Industry Median: 15.55
vs FRA:9OF: 30.60
BioRestorative Therapies (FRA:9OF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
BioRestorative Therapies EBIT per Share Related Terms
BioRestorative Therapies EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioRestorative Therapies (FRA:9OF) has a EBIT per Share of €-1.18 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioRestorative Therapies and its competitors. According to the industry distribution chart, BioRestorative Therapies ranks #364 out of 1178 companies in the Biotechnology industry, placing it in the top 30.9%.
Is BioRestorative Therapies' EBIT per Share too high?
BioRestorative Therapies' current EBIT per Share is €-1.18. Based on the distribution chart, BioRestorative Therapies ranks #364 out of 1178 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' EBIT per Share compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #364 out of 1178 companies for EBIT per Share. This puts BioRestorative Therapies in the upper half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current EBIT per Share is €-1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.30, compared to a current price of €0.34 — trading 73.7% below its estimated fair value. The current EBIT per Share is €-1.18. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current EBIT per Share is €-1.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.34 is trading 73.7% below its estimated GF Value™ of €1.30.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
EBIT per Share: €-1.18
GF Value™: €1.30 vs. price of €0.34 (73.7% below fair value)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score
Get the complete analysis for FRA:9OF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
